X4 Pharmaceuticals Inc
XFOR
查看详细走势图
3.560USD
-0.100-2.73%
收盘 02/06, 16:00（美东）报价延迟15分钟
89.52M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.73%
5天
-3.78%
1月
-10.10%
6月
+125.32%
今年开始到现在
-11.00%
1年
-78.43%
查看详细走势图
TradingKey X4 Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
X4 Pharmaceuticals Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在药品行业排名114/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价8.00。中期看，股价处于平稳状态。近一个月，市场表现较差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
X4 Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
X4 Pharmaceuticals Inc亮点
亮点风险
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
业绩增长期
公司处于发展阶段，最新年度总收入2.56M美元
估值高估
公司最新PE估值-0.40，处于3年历史高位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值19.18K
活跃度增加
近期活跃度增加，过去20天平均换手率13.21
分析师目标
根据
4
位分析师
买入
评级
8.000
目标均价
+118.58%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
X4 Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
X4 Pharmaceuticals Inc简介
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
公司代码XFOR
公司X4 Pharmaceuticals Inc
CEO
网址https://www.x4pharma.com/
相关品种
